CD8A and neoplasm: Although blockade of certain individual inhibitory receptor with specific antibodies has shown significant promise in overcoming immune suppression and mediating tumor regression [2–4], recent studies indicate that multiple inhibitory receptors (including CD160, KLRG-1, TIM-3, 2B4, BTLA and LAG3) are often co-expressed on tumor-antigen specific CD8+ T cells [5].